ABSTRACT Based on current estimates the number of new colorectal cancer diagnoses will exceed one million over the next seven years. More than half of these patients will be treated with a highly active platinum compound called oxaliplatin. While the approved use of oxaliplatin has, for the first time in over 50 years, improved overall survival, the high incidence of oxaliplatin-induced peripheral neuropathy (and the absence of any preventive strategy) limits the clinical utility of this drug. As such, effective prophylaxis against this toxicity should still be considered a priority for innovative prevention research.
Buy this Article
|